Cardiff Oncology (CRDF) Soars 4.99% on Positive Clinical Trial Results

Cardiff Oncology (CRDF) shares rose to their highest level since March 2025 today, with an intraday gain of 4.99%.

The strategy of buying CRDF shares after they reach a recent high and holding for one week resulted in poor performance over the past five years. The strategy yielded a return of -31.96%, with a Sharpe ratio of -0.17, indicating significant risk and negative returns. The maximum drawdown was -79.34%, and the volatility was 86.14%, suggesting that the strategy carried high risk and resulted in substantial losses.

Cardiff Oncology has recently made significant strides in its clinical trials, particularly with its drug onvansertib. In a Phase 1b clinical study, onvansertib demonstrated promising results in treating aggressive breast cancer, achieving a 40% response rate and showing a good safety profile. This indicates that the drug's efficacy is dose-dependent, which is a positive sign for its potential as a treatment option.

Additionally, positive data was reported from an investigator-initiated trial where onvansertib was used in combination with paclitaxel. This combination therapy showed encouraging results, further supporting the potential of onvansertib as a viable treatment for cancer patients. These developments suggest that Cardiff Oncology is making progress in advancing treatment options for cancer patients, which could have a positive impact on the company's stock performance.